Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.

ABSTRACT:

Background

Cancer vaccines are able to achieve tumor-specific immune editing in early-phase clinical trials. However, the infiltration of cytotoxic T cells into immune-deserted tumors is still a major limiting factor. An optimized vaccine approach to induce antigen-specific T cells that can perform robust tumor infiltration is important to accelerate their clinical translation. We previously developed a STING-activating PC7A nanovaccine that produces a strong anti-tumor T cell response on subcutaneous injection. This study systematically investigated the impact of administration methods on the performance of nanovaccines.

Methods

Tumor growth inhibition by intratumoral delivery and subcutaneous delivery of nanovaccine was investigated in TC-1 human papillomavirus-induced can

SUBMITTER: Jiang X 

PROVIDER: S-EPMC9150169 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature